Cytokinetics Financial Statements
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytokinetics revenue and earnings
In fiscal 2025, Cytokinetics generated $88.0 million in revenue, up 376.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Cytokinetics reported a net loss of $785.0 million, compared with a loss of $589.5 million a year earlier. Operating margin was -695.4%.
Diluted earnings per share came in at -$6.54. Over the last 5 fiscal years, CYTK's revenue has grown at a 9.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Cytokinetics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.04M | 18.47M | 7.53M | 94.59M | 70.43M | 55.83M | 26.87M | 31.50M | 13.37M | 106.41M |
| Revenue growth (YoY) | +376.56% | +145.34% | -92.04% | +34.30% | +26.15% | +107.79% | -14.71% | +135.64% | -87.44% | +271.30% |
| Operating Expenses | 700.30M | 554.72M | 503.74M | 418.79M | 256.74M | 149.77M | 125.73M | 120.42M | 126.76M | 87.72M |
| Research & Development | 416.03M | 339.41M | 330.12M | 240.81M | 159.94M | 96.95M | 86.13M | 89.14M | 90.30M | 59.90M |
| Operating Income | -612.26M | -536.25M | -496.20M | -324.20M | -186.31M | -93.94M | -98.87M | -88.92M | -113.40M | 18.69M |
| Interest Expense | 45.58M | 37.70M | 28.31M | 19.41M | 16.44M | 15.96M | 6.62M | 3.80M | 3.02M | 2.70M |
| Other Income (Expense) | 48.42M | 51.53M | 27.63M | 11.34M | 331.00K | 5.33M | 4.54M | 4.19M | 2.60M | 464.00K |
| Pretax Income | — | — | — | — | — | — | — | -106.29M | -127.79M | 16.45M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -784.96M | -589.53M | -526.24M | -388.95M | -215.31M | -127.29M | -121.69M | -106.29M | -127.79M | 16.45M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | -876.70% | — |
| EPS (Basic) | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 | -1.95 | -2.59 | 0.41 |
| EPS (Diluted) | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 | -1.95 | -2.59 | 0.39 |
| Shares Outstanding (Basic) | 120.10K | 111.98K | 96.52K | 89.83K | 76.89K | 64.52K | 57.58K | 54.42K | 49.40M | 39.94M |
| Shares Outstanding (Diluted) | 120.10K | 111.98K | 96.52K | 89.83K | 76.89K | 64.52K | 57.58K | 54.42K | 49.40M | 42.56M |
| EBITDA | -602.13M | -526.72M | -484.31M | -318.39M | -184.04M | -92.11M | -97.57M | -87.68M | -111.48M | 19.43M |
| Operating Margin | -695.44% | -2902.72% | -6589.71% | -342.75% | -264.54% | -168.27% | -367.97% | -282.26% | -848.26% | 17.56% |
| Net Margin | -891.60% | -3191.11% | -6988.63% | -411.21% | -305.72% | -228.00% | -452.93% | -337.41% | -955.94% | 15.46% |
This table shows 10 annual periods of Cytokinetics's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CYTK's reporting calendar. What is a income statement?